108 related articles for article (PubMed ID: 24429007)
1. Keeping sterile water for injection cold enough for reconstitution of azacitidine in isolators.
Savry A; Correard F; Villano LG; Pisano P; Pourroy B
Am J Health Syst Pharm; 2014 Feb; 71(3):180-1. PubMed ID: 24429007
[No Abstract] [Full Text] [Related]
2. Keeping sterile 0.9% sodium chloride, 5% dextrose, and lactated Ringer's solutions for injection cold enough for dilution of decitabine in isolators.
Correard F; Savry A; Espitallier F; Villano LG; Pisano P; Pourroy B
Am J Health Syst Pharm; 2016 Jun; 73(11):748-50. PubMed ID: 27208058
[No Abstract] [Full Text] [Related]
3. Stability of azacitidine suspensions.
Duriez A; Vigneron JH; Zenier HA; May I; Demoré BM
Ann Pharmacother; 2011 Apr; 45(4):546. PubMed ID: 21487087
[No Abstract] [Full Text] [Related]
4. Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes.
Guirguis HR; Charbonneau LF; Tyono I; Wells RA; Cheung MC; Buckstein R
Leuk Lymphoma; 2015 Feb; 56(2):542-4. PubMed ID: 24882261
[No Abstract] [Full Text] [Related]
5. Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage.
Legeron R; Xuereb F; Djabarouti S; Saux MC; Breilh D
Am J Health Syst Pharm; 2013 Dec; 70(23):2137-42. PubMed ID: 24249764
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine: a novel agent for myelodysplastic syndromes.
Sullivan M; Hahn K; Kolesar JM
Am J Health Syst Pharm; 2005 Aug; 62(15):1567-73. PubMed ID: 16030365
[TBL] [Abstract][Full Text] [Related]
7. Basic Principles of Lyophilization, Part 1.
Akers MJ
Int J Pharm Compd; 2015; 19(6):471-6. PubMed ID: 26891561
[TBL] [Abstract][Full Text] [Related]
8. Decitabine in myelodysplastic syndromes: viewpoints.
Garcia-Manero G; Saba HI
Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
[No Abstract] [Full Text] [Related]
9. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
10. Decitabine.
Gore SD; Jones C; Kirkpatrick P
Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
[No Abstract] [Full Text] [Related]
11. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
Voso MT; Fianchi L; Criscuolo M; Greco M; D'Alo F; Hohaus S; Pagano L; Leone G
Leuk Res; 2012 Jan; 36(1):e15-7. PubMed ID: 21907408
[No Abstract] [Full Text] [Related]
12. Intravenous azacitidine for MDS.
Gore SD
Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
[No Abstract] [Full Text] [Related]
13. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
[No Abstract] [Full Text] [Related]
15. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
[No Abstract] [Full Text] [Related]
17. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Kantarjian HM
J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
[No Abstract] [Full Text] [Related]
18. Azacitine (vidaza) for myelodysplastic syndrome.
Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
[TBL] [Abstract][Full Text] [Related]
19. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
[No Abstract] [Full Text] [Related]
20. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
